<unk>  works by binding to the active site of the neuraminidase protein, rendering the influenza virus unable to escape its host cell and infect others. It is also an inhibitor of influenza virus replication in vitro and in vivo. In clinical trials,<unk>  was found to reduce the time-to-symptom resolution by 1.5 days if therapy was started within 48 hours of the onset of symptoms. The bioavailability of<unk>  is 2%. After inhalation,<unk>  is concentrated in the lungs and oropharynx, where up to 15% of the dose is absorbed and excreted in urine.
Zanamivir
Oseltamivir
Peramivir
Quifenadine
Inadine
Rimantadine
Umifenovir
Faricimab